Carrier Screening Market by Type, Medical Condition, Technology, End-User

List of Tables

The Carrier Screening Market was valued at USD 3.07 billion in 2023, expected to reach USD 3.52 billion in 2024, and is projected to grow at a CAGR of 14.93%, to USD 8.13 billion by 2030.

Carrier screening is a genetic testing procedure used to determine if an individual is a carrier of a specific genetic mutation that could potentially be passed on to their offspring. Its scope extends to identifying carriers of autosomal recessive and X-linked genetic disorders, providing vital information for family planning. The necessity of carrier screening arises from its potential to prevent the transmission of genetic disorders, making it an essential tool in preventive healthcare and reproductive planning. It finds applications in pre-pregnancy and prenatal contexts, aiding prospective parents in making informed reproductive choices. The end-use scope primarily involves hospitals, diagnostic laboratories, and private clinics.

KEY MARKET STATISTICS
Base Year [2023]	USD 3.07 billion
Estimated Year [2024]	USD 3.52 billion
Forecast Year [2030]	USD 8.13 billion
CAGR (%)	14.93%

The market for carrier screening is primarily driven by increasing awareness of genetic disorders, advancements in genetic testing technologies, and the rising prevalence of genetic conditions. Key growth factors include the integration of next-generation sequencing (NGS) technologies that offer a broader and more accurate analysis of genetic mutations. The expansion of telehealth and at-home testing kits provides new opportunities, enabling wider accessibility and convenience for users. Companies should consider investing in strategic collaborations and improving the cost-efficiency of tests to tap into these opportunities.

However, the market faces limitations such as high costs of testing, ethical considerations, and regulatory challenges. The potential of false positives or negatives can result in unforeseen ethical dilemmas, impacting market growth. Moreover, the need for genetic counseling following test results adds to the complexity and cost. To foster innovation, focusing on developing more affordable screening technologies, improving test accuracy, and enhancing user-friendly interfaces for consumer engagement is crucial. Researching into gene therapy and editing techniques CRISPR could also provide pathways for future growth. The nature of the carrier screening market is dynamic and evolving, characterized by rapid technological advancements and regulatory developments. Business growth can be bolstered by investing in patient education initiatives to enhance awareness and acceptance among potential users.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Carrier Screening Market

The Carrier Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Growing prevalence of inherited diseases and focus on early disease detection and prevention
- Rising geriatric population and high risk of chromosomal abnormalities
- Increasing investment in healthcare infrastructure and government initiatives for the management of genetic disorders
Market Restraints
- Dearth of skilled professionals and professional services
Market Opportunities
- Emerging improvements in POC diagnostics
- Technological advancements in carrier screening
Market Challenges
- Presence of non-uniform standards and guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Carrier Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Carrier Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Carrier Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Carrier Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Carrier Screening Market

A detailed market share analysis in the Carrier Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Carrier Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Carrier Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Carrier Screening Market

A strategic analysis of the Carrier Screening Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Carrier Screening Market, highlighting leading vendors and their innovative profiles. These include 23Andme Inc., Abbott Laboratories, Ambry Genetics Corporation by Konica Minolta, Inc., Asper Biogene, Autogenomics Inc. by Prescient Medicine Holdings Inc., BGI Genomics Co., Ltd., Biora Therapeutics, Inc., CENTOGENE N.V., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Gene by Gene, Ltd. by myDNA Inc., GeneDx Holdings Corp., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation by DiaSorin Company, MedGenome Labs Ltd., Myriad Genetics, Inc., Natera, Inc., OPKO Health, Inc., Otogenetics Corporation, Quest Diagnostics Inc., Thermo Fisher Scientific Inc., and TRUE HEALTH LABS.

Market Segmentation & Coverage

This research report categorizes the Carrier Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Type, market is studied across Expanded Carrier Screening and Targeted Disease Carrier Screening. The Expanded Carrier Screening is further studied across Customized Panel Testing and Predesigned Panel Testing.
Based on Medical Condition, market is studied across Hematological Conditions, Neurological Conditions, and Pulmonary Conditions.
Based on Technology, market is studied across DNA Sequencing, Microarrays, and Polymerase Chain Reaction.
Based on End-User, market is studied across Hospitals, Physician Offices & Clinics, and Reference Laboratories.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-034230D3E2DE

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing prevalence of inherited diseases and focus on early disease detection and prevention
  - 5.1.1.2. Rising geriatric population and high risk of chromosomal abnormalities
  - 5.1.1.3. Increasing investment in healthcare infrastructure and government initiatives for the management of genetic disorders
- 5.1.2. Restraints
  - 5.1.2.1. Dearth of skilled professionals and professional services
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging improvements in POC diagnostics
  - 5.1.3.2. Technological advancements in carrier screening
- 5.1.4. Challenges
  - 5.1.4.1. Presence of non-uniform standards and guidelines
5.2. Market Segmentation Analysis
- 5.2.1. Type: Expanded carrier screening (ECS) offers a wide overview of genetic health and conditions
- 5.2.2. End-User: Evolving application of carrier screening in hospitals
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Carrier Screening Market, by Type

6.1. Introduction
6.2. Expanded Carrier Screening
- 6.2.1. Customized Panel Testing
- 6.2.2. Predesigned Panel Testing
6.3. Targeted Disease Carrier Screening

7. Carrier Screening Market, by Medical Condition

7.1. Introduction
7.2. Hematological Conditions
7.3. Neurological Conditions
7.4. Pulmonary Conditions

8. Carrier Screening Market, by Technology

8.1. Introduction
8.2. DNA Sequencing
8.3. Microarrays
8.4. Polymerase Chain Reaction

9. Carrier Screening Market, by End-User

9.1. Introduction
9.2. Hospitals
9.3. Physician Offices & Clinics
9.4. Reference Laboratories

10. Americas Carrier Screening Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Carrier Screening Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Carrier Screening Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Invitae Completes Sale of Reproductive Health Assets to Natera
- 13.3.2. Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
- 13.3.3. Bio-Techne and Oxford Nanopore Technologies Partner to Bring Innovative Reproductive Health and Carrier Screening Solutions to the Market
13.4. Strategy Analysis & Recommendation

Companies Mentioned

1. 23Andme Inc.
2. Abbott Laboratories
3. Ambry Genetics Corporation by Konica Minolta, Inc.
4. Asper Biogene
5. Autogenomics Inc. by Prescient Medicine Holdings Inc.
6. BGI Genomics Co., Ltd.
7. Biora Therapeutics, Inc.
8. CENTOGENE N.V.
9. Danaher Corporation
10. Eurofins Scientific
11. F. Hoffmann-La Roche Ltd.
12. Fulgent Genetics, Inc.
13. Gene by Gene, Ltd. by myDNA Inc.
14. GeneDx Holdings Corp.
15. Illumina Inc.
16. Invitae Corporation
17. Laboratory Corporation of America Holdings
18. Luminex Corporation by DiaSorin Company
19. MedGenome Labs Ltd.
20. Myriad Genetics, Inc.
21. Natera, Inc.
22. OPKO Health, Inc.
23. Otogenetics Corporation
24. Quest Diagnostics Inc.
25. Thermo Fisher Scientific Inc.
26. TRUE HEALTH LABS